News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merrimack Pharmaceuticals Inc. Initiates Phase 2 Clinical Study of MM-111 in Advanced Gastroesophageal Cancers


7/22/2013 9:05:36 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., July 22, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the enrollment of its first patient in a Phase 2 clinical trial of its bispecific antibody, MM-111, for the treatment of advanced gastric, esophageal and gastroesophageal junction (GEJ) cancers.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES